nodes	percent_of_prediction	percent_of_DWPC	metapath
Metyrapone—ABCC3—Fluorouracil—urinary bladder cancer	0.16	0.204	CbGbCtD
Metyrapone—ABCC3—Cisplatin—urinary bladder cancer	0.136	0.174	CbGbCtD
Metyrapone—ABCC3—Etoposide—urinary bladder cancer	0.134	0.171	CbGbCtD
Metyrapone—ABCC3—Doxorubicin—urinary bladder cancer	0.0912	0.116	CbGbCtD
Metyrapone—ABCC3—Methotrexate—urinary bladder cancer	0.0883	0.113	CbGbCtD
Metyrapone—CYP2A6—Fluorouracil—urinary bladder cancer	0.0711	0.0908	CbGbCtD
Metyrapone—CYP3A4—Thiotepa—urinary bladder cancer	0.0438	0.0559	CbGbCtD
Metyrapone—CYP2E1—Etoposide—urinary bladder cancer	0.0392	0.05	CbGbCtD
Metyrapone—CYP3A4—Etoposide—urinary bladder cancer	0.0119	0.0151	CbGbCtD
Metyrapone—CYP3A4—Doxorubicin—urinary bladder cancer	0.00809	0.0103	CbGbCtD
Metyrapone—CYP11B2—renal system—urinary bladder cancer	0.00347	0.126	CbGeAlD
Metyrapone—CYP2E1—urine—urinary bladder cancer	0.00316	0.115	CbGeAlD
Metyrapone—CYP3A4—urine—urinary bladder cancer	0.00254	0.0924	CbGeAlD
Metyrapone—CYP2A6—prostate gland—urinary bladder cancer	0.0024	0.0872	CbGeAlD
Metyrapone—ABCC3—prostate gland—urinary bladder cancer	0.00225	0.0817	CbGeAlD
Metyrapone—CYP2A6—seminal vesicle—urinary bladder cancer	0.00203	0.0738	CbGeAlD
Metyrapone—Endocrine disorder—Thiotepa—urinary bladder cancer	0.00176	0.0299	CcSEcCtD
Metyrapone—Pancytopenia—Mitomycin—urinary bladder cancer	0.00173	0.0294	CcSEcCtD
Metyrapone—Dermatitis atopic—Gemcitabine—urinary bladder cancer	0.00166	0.0282	CcSEcCtD
Metyrapone—CYP11B2—lymph node—urinary bladder cancer	0.00163	0.0592	CbGeAlD
Metyrapone—ABCC3—renal system—urinary bladder cancer	0.00153	0.0557	CbGeAlD
Metyrapone—Alopecia—Mitomycin—urinary bladder cancer	0.00129	0.0219	CcSEcCtD
Metyrapone—Gastrointestinal pain—Valrubicin—urinary bladder cancer	0.00123	0.0209	CcSEcCtD
Metyrapone—ABCC3—female reproductive system—urinary bladder cancer	0.00123	0.0446	CbGeAlD
Metyrapone—Pain—Carboplatin—urinary bladder cancer	0.00119	0.0202	CcSEcCtD
Metyrapone—Abdominal pain—Valrubicin—urinary bladder cancer	0.00119	0.0202	CcSEcCtD
Metyrapone—CYP2A6—vagina—urinary bladder cancer	0.00118	0.0431	CbGeAlD
Metyrapone—CYP2E1—prostate gland—urinary bladder cancer	0.00113	0.0412	CbGeAlD
Metyrapone—Hypertension—Mitomycin—urinary bladder cancer	0.0011	0.0186	CcSEcCtD
Metyrapone—Dizziness—Valrubicin—urinary bladder cancer	0.000996	0.0169	CcSEcCtD
Metyrapone—CYP2E1—seminal vesicle—urinary bladder cancer	0.000958	0.0349	CbGeAlD
Metyrapone—Vomiting—Valrubicin—urinary bladder cancer	0.000958	0.0162	CcSEcCtD
Metyrapone—Headache—Valrubicin—urinary bladder cancer	0.000943	0.016	CcSEcCtD
Metyrapone—Bone marrow depression—Methotrexate—urinary bladder cancer	0.000932	0.0158	CcSEcCtD
Metyrapone—Nausea—Valrubicin—urinary bladder cancer	0.000895	0.0152	CcSEcCtD
Metyrapone—Pain—Mitomycin—urinary bladder cancer	0.000887	0.015	CcSEcCtD
Metyrapone—Bone marrow depression—Epirubicin—urinary bladder cancer	0.000872	0.0148	CcSEcCtD
Metyrapone—Pancytopenia—Thiotepa—urinary bladder cancer	0.000871	0.0148	CcSEcCtD
Metyrapone—Bone marrow depression—Doxorubicin—urinary bladder cancer	0.000807	0.0137	CcSEcCtD
Metyrapone—Dermatitis atopic—Epirubicin—urinary bladder cancer	0.000796	0.0135	CcSEcCtD
Metyrapone—CYP2E1—renal system—urinary bladder cancer	0.000772	0.0281	CbGeAlD
Metyrapone—CYP2E1—urethra—urinary bladder cancer	0.000759	0.0276	CbGeAlD
Metyrapone—Dermatitis atopic—Doxorubicin—urinary bladder cancer	0.000736	0.0125	CcSEcCtD
Metyrapone—Pancytopenia—Gemcitabine—urinary bladder cancer	0.000733	0.0124	CcSEcCtD
Metyrapone—Pancytopenia—Fluorouracil—urinary bladder cancer	0.000721	0.0122	CcSEcCtD
Metyrapone—ABCC3—lymph node—urinary bladder cancer	0.000717	0.0261	CbGeAlD
Metyrapone—Abdominal discomfort—Cisplatin—urinary bladder cancer	0.00069	0.0117	CcSEcCtD
Metyrapone—Dizziness—Mitomycin—urinary bladder cancer	0.000686	0.0116	CcSEcCtD
Metyrapone—Pancytopenia—Cisplatin—urinary bladder cancer	0.000683	0.0116	CcSEcCtD
Metyrapone—Angiopathy—Thiotepa—urinary bladder cancer	0.000666	0.0113	CcSEcCtD
Metyrapone—Vomiting—Mitomycin—urinary bladder cancer	0.00066	0.0112	CcSEcCtD
Metyrapone—Headache—Mitomycin—urinary bladder cancer	0.00065	0.011	CcSEcCtD
Metyrapone—Alopecia—Thiotepa—urinary bladder cancer	0.000649	0.011	CcSEcCtD
Metyrapone—Pancytopenia—Etoposide—urinary bladder cancer	0.000626	0.0106	CcSEcCtD
Metyrapone—CYP3A4—renal system—urinary bladder cancer	0.000621	0.0226	CbGeAlD
Metyrapone—CYP2E1—female reproductive system—urinary bladder cancer	0.000618	0.0225	CbGeAlD
Metyrapone—Nausea—Mitomycin—urinary bladder cancer	0.000616	0.0104	CcSEcCtD
Metyrapone—Angiopathy—Gemcitabine—urinary bladder cancer	0.000561	0.0095	CcSEcCtD
Metyrapone—Hypertension—Thiotepa—urinary bladder cancer	0.000552	0.00936	CcSEcCtD
Metyrapone—Alopecia—Gemcitabine—urinary bladder cancer	0.000546	0.00925	CcSEcCtD
Metyrapone—Unspecified disorder of skin and subcutaneous tissue—Thiotepa—urinary bladder cancer	0.000541	0.00916	CcSEcCtD
Metyrapone—Alopecia—Fluorouracil—urinary bladder cancer	0.000537	0.0091	CcSEcCtD
Metyrapone—Nervous system disorder—Thiotepa—urinary bladder cancer	0.000512	0.00867	CcSEcCtD
Metyrapone—Alopecia—Cisplatin—urinary bladder cancer	0.000509	0.00863	CcSEcCtD
Metyrapone—Skin disorder—Thiotepa—urinary bladder cancer	0.000507	0.00859	CcSEcCtD
Metyrapone—CYP3A4—female reproductive system—urinary bladder cancer	0.000498	0.0181	CbGeAlD
Metyrapone—Angiopathy—Etoposide—urinary bladder cancer	0.000479	0.00811	CcSEcCtD
Metyrapone—Alopecia—Etoposide—urinary bladder cancer	0.000466	0.0079	CcSEcCtD
Metyrapone—Hypertension—Gemcitabine—urinary bladder cancer	0.000464	0.00787	CcSEcCtD
Metyrapone—Unspecified disorder of skin and subcutaneous tissue—Gemcitabine—urinary bladder cancer	0.000455	0.00771	CcSEcCtD
Metyrapone—Gastrointestinal disorder—Thiotepa—urinary bladder cancer	0.00045	0.00764	CcSEcCtD
Metyrapone—Pain—Thiotepa—urinary bladder cancer	0.000446	0.00756	CcSEcCtD
Metyrapone—Nervous system disorder—Gemcitabine—urinary bladder cancer	0.00043	0.0073	CcSEcCtD
Metyrapone—Gastrointestinal pain—Thiotepa—urinary bladder cancer	0.000427	0.00723	CcSEcCtD
Metyrapone—Skin disorder—Gemcitabine—urinary bladder cancer	0.000426	0.00723	CcSEcCtD
Metyrapone—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—urinary bladder cancer	0.000424	0.00718	CcSEcCtD
Metyrapone—Nervous system disorder—Fluorouracil—urinary bladder cancer	0.000423	0.00717	CcSEcCtD
Metyrapone—CYP2E1—Biological oxidations—NAT1—urinary bladder cancer	0.000417	0.0032	CbGpPWpGaD
Metyrapone—CYP3A4—Estrogen metabolism—NQO1—urinary bladder cancer	0.000416	0.00319	CbGpPWpGaD
Metyrapone—Abdominal pain—Thiotepa—urinary bladder cancer	0.000412	0.00699	CcSEcCtD
Metyrapone—CYP2E1—Metapathway biotransformation—GSTO2—urinary bladder cancer	0.000412	0.00316	CbGpPWpGaD
Metyrapone—Hypotension—Gemcitabine—urinary bladder cancer	0.00041	0.00695	CcSEcCtD
Metyrapone—Hypotension—Fluorouracil—urinary bladder cancer	0.000403	0.00684	CcSEcCtD
Metyrapone—Nervous system disorder—Cisplatin—urinary bladder cancer	0.000401	0.0068	CcSEcCtD
Metyrapone—CYP11B2—Biological oxidations—GSTP1—urinary bladder cancer	0.0004	0.00307	CbGpPWpGaD
Metyrapone—Skin disorder—Cisplatin—urinary bladder cancer	0.000397	0.00674	CcSEcCtD
Metyrapone—Hypertension—Etoposide—urinary bladder cancer	0.000396	0.00672	CcSEcCtD
Metyrapone—CYP11B2—Metapathway biotransformation—GSTP1—urinary bladder cancer	0.000395	0.00303	CbGpPWpGaD
Metyrapone—Unspecified disorder of skin and subcutaneous tissue—Etoposide—urinary bladder cancer	0.000388	0.00658	CcSEcCtD
Metyrapone—Hypotension—Cisplatin—urinary bladder cancer	0.000382	0.00648	CcSEcCtD
Metyrapone—CYP2E1—Biological oxidations—UGT2B7—urinary bladder cancer	0.000382	0.00293	CbGpPWpGaD
Metyrapone—Gastrointestinal disorder—Gemcitabine—urinary bladder cancer	0.000379	0.00642	CcSEcCtD
Metyrapone—Abdominal discomfort—Methotrexate—urinary bladder cancer	0.000378	0.00642	CcSEcCtD
Metyrapone—CYP2E1—Metapathway biotransformation—UGT2B7—urinary bladder cancer	0.000376	0.00289	CbGpPWpGaD
Metyrapone—Pain—Gemcitabine—urinary bladder cancer	0.000375	0.00636	CcSEcCtD
Metyrapone—Pancytopenia—Methotrexate—urinary bladder cancer	0.000375	0.00636	CcSEcCtD
Metyrapone—Gastrointestinal disorder—Fluorouracil—urinary bladder cancer	0.000373	0.00632	CcSEcCtD
Metyrapone—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP4B1—urinary bladder cancer	0.00037	0.00284	CbGpPWpGaD
Metyrapone—CYP11B1—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	0.00037	0.00284	CbGpPWpGaD
Metyrapone—Pain—Fluorouracil—urinary bladder cancer	0.000369	0.00626	CcSEcCtD
Metyrapone—CYP11B2—Biological oxidations—GSTM1—urinary bladder cancer	0.000368	0.00282	CbGpPWpGaD
Metyrapone—CYP3A4—Oxidation by Cytochrome P450—CYP4B1—urinary bladder cancer	0.000365	0.00281	CbGpPWpGaD
Metyrapone—Skin disorder—Etoposide—urinary bladder cancer	0.000364	0.00617	CcSEcCtD
Metyrapone—CYP11B2—Metapathway biotransformation—GSTM1—urinary bladder cancer	0.000363	0.00278	CbGpPWpGaD
Metyrapone—Gastrointestinal disorder—Cisplatin—urinary bladder cancer	0.000353	0.00599	CcSEcCtD
Metyrapone—Pancytopenia—Epirubicin—urinary bladder cancer	0.000351	0.00595	CcSEcCtD
Metyrapone—Hypotension—Etoposide—urinary bladder cancer	0.00035	0.00594	CcSEcCtD
Metyrapone—Pain—Cisplatin—urinary bladder cancer	0.00035	0.00593	CcSEcCtD
Metyrapone—Dizziness—Thiotepa—urinary bladder cancer	0.000345	0.00585	CcSEcCtD
Metyrapone—CYP11B1—Biological oxidations—GSTP1—urinary bladder cancer	0.000345	0.00265	CbGpPWpGaD
Metyrapone—CYP2E1—Biological oxidations—CYP4B1—urinary bladder cancer	0.000344	0.00264	CbGpPWpGaD
Metyrapone—CYP11B1—Metapathway biotransformation—GSTP1—urinary bladder cancer	0.00034	0.00261	CbGpPWpGaD
Metyrapone—ABCC3—NRF2 pathway—NQO1—urinary bladder cancer	0.000339	0.00261	CbGpPWpGaD
Metyrapone—CYP2E1—Metapathway biotransformation—CYP4B1—urinary bladder cancer	0.000339	0.0026	CbGpPWpGaD
Metyrapone—Vomiting—Thiotepa—urinary bladder cancer	0.000332	0.00562	CcSEcCtD
Metyrapone—Headache—Thiotepa—urinary bladder cancer	0.000327	0.00554	CcSEcCtD
Metyrapone—CYP11B1—Corticotropin-releasing hormone—RHOA—urinary bladder cancer	0.000325	0.0025	CbGpPWpGaD
Metyrapone—Pancytopenia—Doxorubicin—urinary bladder cancer	0.000325	0.0055	CcSEcCtD
Metyrapone—Gastrointestinal disorder—Etoposide—urinary bladder cancer	0.000324	0.00549	CcSEcCtD
Metyrapone—Pain—Etoposide—urinary bladder cancer	0.000321	0.00543	CcSEcCtD
Metyrapone—CYP3A4—Estrogen metabolism—GSTM1—urinary bladder cancer	0.000319	0.00245	CbGpPWpGaD
Metyrapone—CYP11B1—Biological oxidations—GSTM1—urinary bladder cancer	0.000317	0.00243	CbGpPWpGaD
Metyrapone—CYP11B1—Metapathway biotransformation—GSTM1—urinary bladder cancer	0.000312	0.0024	CbGpPWpGaD
Metyrapone—Nausea—Thiotepa—urinary bladder cancer	0.00031	0.00525	CcSEcCtD
Metyrapone—ABCC3—Transmembrane transport of small molecules—SLC14A2—urinary bladder cancer	0.000308	0.00236	CbGpPWpGaD
Metyrapone—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.000306	0.0052	CcSEcCtD
Metyrapone—CYP3A4—Phase 1 - Functionalization of compounds—CYP4B1—urinary bladder cancer	0.0003	0.0023	CbGpPWpGaD
Metyrapone—CYP3A4—Constitutive Androstane Receptor Pathway—SMC1A—urinary bladder cancer	0.000299	0.0023	CbGpPWpGaD
Metyrapone—Abdominal pain—Etoposide—urinary bladder cancer	0.000296	0.00502	CcSEcCtD
Metyrapone—CYP2E1—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—urinary bladder cancer	0.000296	0.00227	CbGpPWpGaD
Metyrapone—CYP2A6—Biological oxidations—NAT2—urinary bladder cancer	0.000289	0.00222	CbGpPWpGaD
Metyrapone—ABCC3—Fluoropyrimidine Activity—TP53—urinary bladder cancer	0.000287	0.0022	CbGpPWpGaD
Metyrapone—Angiopathy—Methotrexate—urinary bladder cancer	0.000287	0.00486	CcSEcCtD
Metyrapone—CYP11B1—Corticotropin-releasing hormone—CXCL8—urinary bladder cancer	0.000286	0.00219	CbGpPWpGaD
Metyrapone—Dizziness—Fluorouracil—urinary bladder cancer	0.000285	0.00484	CcSEcCtD
Metyrapone—ABCC3—NRF2 pathway—GSTP1—urinary bladder cancer	0.000283	0.00217	CbGpPWpGaD
Metyrapone—Alopecia—Methotrexate—urinary bladder cancer	0.000279	0.00473	CcSEcCtD
Metyrapone—Vomiting—Gemcitabine—urinary bladder cancer	0.000279	0.00473	CcSEcCtD
Metyrapone—Headache—Gemcitabine—urinary bladder cancer	0.000275	0.00466	CcSEcCtD
Metyrapone—Vomiting—Fluorouracil—urinary bladder cancer	0.000274	0.00465	CcSEcCtD
Metyrapone—CYP11B1—Corticotropin-releasing hormone—IL2—urinary bladder cancer	0.000273	0.0021	CbGpPWpGaD
Metyrapone—Headache—Fluorouracil—urinary bladder cancer	0.00027	0.00458	CcSEcCtD
Metyrapone—Angiopathy—Epirubicin—urinary bladder cancer	0.000268	0.00455	CcSEcCtD
Metyrapone—ABCC3—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	0.000267	0.00205	CbGpPWpGaD
Metyrapone—Alopecia—Epirubicin—urinary bladder cancer	0.000261	0.00443	CcSEcCtD
Metyrapone—Nausea—Gemcitabine—urinary bladder cancer	0.000261	0.00442	CcSEcCtD
Metyrapone—Vomiting—Cisplatin—urinary bladder cancer	0.00026	0.00441	CcSEcCtD
Metyrapone—ABCC3—NRF2 pathway—GSTM1—urinary bladder cancer	0.00026	0.002	CbGpPWpGaD
Metyrapone—Nausea—Fluorouracil—urinary bladder cancer	0.000256	0.00435	CcSEcCtD
Metyrapone—Angiopathy—Doxorubicin—urinary bladder cancer	0.000248	0.00421	CcSEcCtD
Metyrapone—Dizziness—Etoposide—urinary bladder cancer	0.000248	0.0042	CcSEcCtD
Metyrapone—CYP11B2—Metabolism—GSTZ1—urinary bladder cancer	0.000245	0.00188	CbGpPWpGaD
Metyrapone—Nausea—Cisplatin—urinary bladder cancer	0.000243	0.00412	CcSEcCtD
Metyrapone—Alopecia—Doxorubicin—urinary bladder cancer	0.000242	0.0041	CcSEcCtD
Metyrapone—Vomiting—Etoposide—urinary bladder cancer	0.000238	0.00404	CcSEcCtD
Metyrapone—Headache—Etoposide—urinary bladder cancer	0.000235	0.00398	CcSEcCtD
Metyrapone—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	0.000233	0.00394	CcSEcCtD
Metyrapone—CYP11B2—Metabolism—GSTO2—urinary bladder cancer	0.000232	0.00178	CbGpPWpGaD
Metyrapone—CYP11B2—Metabolism—NAT1—urinary bladder cancer	0.000232	0.00178	CbGpPWpGaD
Metyrapone—CYP2A6—Biological oxidations—HPGDS—urinary bladder cancer	0.000231	0.00178	CbGpPWpGaD
Metyrapone—CYP2E1—Biological oxidations—NAT2—urinary bladder cancer	0.000229	0.00176	CbGpPWpGaD
Metyrapone—CYP11B2—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	0.000228	0.00175	CbGpPWpGaD
Metyrapone—CYP2E1—Metapathway biotransformation—NAT2—urinary bladder cancer	0.000225	0.00173	CbGpPWpGaD
Metyrapone—CYP2A6—Biological oxidations—GSTT1—urinary bladder cancer	0.000224	0.00172	CbGpPWpGaD
Metyrapone—Nausea—Etoposide—urinary bladder cancer	0.000223	0.00377	CcSEcCtD
Metyrapone—ABCC3—Transmembrane transport of small molecules—AQP3—urinary bladder cancer	0.000223	0.00171	CbGpPWpGaD
Metyrapone—Hypertension—Epirubicin—urinary bladder cancer	0.000222	0.00377	CcSEcCtD
Metyrapone—Nervous system disorder—Methotrexate—urinary bladder cancer	0.00022	0.00373	CcSEcCtD
Metyrapone—Skin disorder—Methotrexate—urinary bladder cancer	0.000218	0.0037	CcSEcCtD
Metyrapone—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	0.000218	0.00369	CcSEcCtD
Metyrapone—CYP2A6—NRF2 pathway—NQO1—urinary bladder cancer	0.000213	0.00163	CbGpPWpGaD
Metyrapone—CYP11B2—Metabolism—UGT2B7—urinary bladder cancer	0.000212	0.00163	CbGpPWpGaD
Metyrapone—CYP11B1—Metabolism—GSTZ1—urinary bladder cancer	0.000211	0.00162	CbGpPWpGaD
Metyrapone—Hypotension—Methotrexate—urinary bladder cancer	0.00021	0.00356	CcSEcCtD
Metyrapone—Nervous system disorder—Epirubicin—urinary bladder cancer	0.000206	0.00349	CcSEcCtD
Metyrapone—Hypertension—Doxorubicin—urinary bladder cancer	0.000206	0.00349	CcSEcCtD
Metyrapone—CYP3A4—Biological oxidations—GSTZ1—urinary bladder cancer	0.000204	0.00157	CbGpPWpGaD
Metyrapone—Skin disorder—Epirubicin—urinary bladder cancer	0.000204	0.00346	CcSEcCtD
Metyrapone—CYP3A4—Metapathway biotransformation—GSTZ1—urinary bladder cancer	0.000201	0.00155	CbGpPWpGaD
Metyrapone—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	0.000201	0.00341	CcSEcCtD
Metyrapone—CYP11B1—Metabolism—GSTO2—urinary bladder cancer	0.0002	0.00154	CbGpPWpGaD
Metyrapone—CYP11B1—Metabolism—NAT1—urinary bladder cancer	0.0002	0.00154	CbGpPWpGaD
Metyrapone—CYP11B1—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	0.000197	0.00151	CbGpPWpGaD
Metyrapone—Hypotension—Epirubicin—urinary bladder cancer	0.000196	0.00333	CcSEcCtD
Metyrapone—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	0.000194	0.00329	CcSEcCtD
Metyrapone—CYP3A4—Biological oxidations—GSTO2—urinary bladder cancer	0.000194	0.00149	CbGpPWpGaD
Metyrapone—CYP3A4—Biological oxidations—NAT1—urinary bladder cancer	0.000194	0.00149	CbGpPWpGaD
Metyrapone—Pain—Methotrexate—urinary bladder cancer	0.000192	0.00325	CcSEcCtD
Metyrapone—CYP11B2—Metabolism—CYP4B1—urinary bladder cancer	0.000191	0.00147	CbGpPWpGaD
Metyrapone—CYP3A4—Metapathway biotransformation—GSTO2—urinary bladder cancer	0.000191	0.00147	CbGpPWpGaD
Metyrapone—Nervous system disorder—Doxorubicin—urinary bladder cancer	0.000191	0.00323	CcSEcCtD
Metyrapone—Skin disorder—Doxorubicin—urinary bladder cancer	0.000189	0.0032	CcSEcCtD
Metyrapone—Gastrointestinal pain—Methotrexate—urinary bladder cancer	0.000184	0.00311	CcSEcCtD
Metyrapone—CYP11B1—Metabolism—UGT2B7—urinary bladder cancer	0.000183	0.00141	CbGpPWpGaD
Metyrapone—CYP2E1—Biological oxidations—HPGDS—urinary bladder cancer	0.000183	0.0014	CbGpPWpGaD
Metyrapone—Hypotension—Doxorubicin—urinary bladder cancer	0.000182	0.00308	CcSEcCtD
Metyrapone—ABCC3—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	0.000181	0.00139	CbGpPWpGaD
Metyrapone—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	0.000181	0.00307	CcSEcCtD
Metyrapone—CYP11B2—Metabolism—SLC19A1—urinary bladder cancer	0.000181	0.00139	CbGpPWpGaD
Metyrapone—Pain—Epirubicin—urinary bladder cancer	0.00018	0.00305	CcSEcCtD
Metyrapone—CYP2A6—Fluoropyrimidine Activity—TP53—urinary bladder cancer	0.00018	0.00138	CbGpPWpGaD
Metyrapone—Abdominal pain—Methotrexate—urinary bladder cancer	0.000177	0.00301	CcSEcCtD
Metyrapone—CYP2E1—Biological oxidations—GSTT1—urinary bladder cancer	0.000177	0.00136	CbGpPWpGaD
Metyrapone—CYP2A6—NRF2 pathway—GSTP1—urinary bladder cancer	0.000177	0.00136	CbGpPWpGaD
Metyrapone—CYP3A4—Biological oxidations—UGT2B7—urinary bladder cancer	0.000177	0.00136	CbGpPWpGaD
Metyrapone—CYP11B2—Metabolism—PRSS3—urinary bladder cancer	0.000176	0.00135	CbGpPWpGaD
Metyrapone—CYP3A4—Metapathway biotransformation—UGT2B7—urinary bladder cancer	0.000175	0.00134	CbGpPWpGaD
Metyrapone—Gastrointestinal pain—Epirubicin—urinary bladder cancer	0.000172	0.00291	CcSEcCtD
Metyrapone—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	0.000168	0.00285	CcSEcCtD
Metyrapone—Pain—Doxorubicin—urinary bladder cancer	0.000166	0.00282	CcSEcCtD
Metyrapone—Abdominal pain—Epirubicin—urinary bladder cancer	0.000166	0.00282	CcSEcCtD
Metyrapone—CYP11B1—Metabolism—CYP4B1—urinary bladder cancer	0.000165	0.00127	CbGpPWpGaD
Metyrapone—CYP2A6—NRF2 pathway—GSTM1—urinary bladder cancer	0.000163	0.00125	CbGpPWpGaD
Metyrapone—CYP3A4—Biological oxidations—CYP4B1—urinary bladder cancer	0.000159	0.00122	CbGpPWpGaD
Metyrapone—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	0.000159	0.00269	CcSEcCtD
Metyrapone—CYP3A4—Metapathway biotransformation—CYP4B1—urinary bladder cancer	0.000157	0.00121	CbGpPWpGaD
Metyrapone—CYP11B1—Metabolism—SLC19A1—urinary bladder cancer	0.000156	0.0012	CbGpPWpGaD
Metyrapone—CYP2A6—Biological oxidations—GSTP1—urinary bladder cancer	0.000155	0.00119	CbGpPWpGaD
Metyrapone—Abdominal pain—Doxorubicin—urinary bladder cancer	0.000154	0.00261	CcSEcCtD
Metyrapone—ABCC3—Metabolism—GSTZ1—urinary bladder cancer	0.000152	0.00117	CbGpPWpGaD
Metyrapone—CYP11B1—Metabolism—PRSS3—urinary bladder cancer	0.000152	0.00117	CbGpPWpGaD
Metyrapone—Dizziness—Methotrexate—urinary bladder cancer	0.000148	0.00252	CcSEcCtD
Metyrapone—ABCC3—Metabolism—GSTO2—urinary bladder cancer	0.000144	0.00111	CbGpPWpGaD
Metyrapone—ABCC3—Metabolism—NAT1—urinary bladder cancer	0.000144	0.00111	CbGpPWpGaD
Metyrapone—CYP2A6—Biological oxidations—GSTM1—urinary bladder cancer	0.000143	0.0011	CbGpPWpGaD
Metyrapone—Vomiting—Methotrexate—urinary bladder cancer	0.000143	0.00242	CcSEcCtD
Metyrapone—ABCC3—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	0.000142	0.00109	CbGpPWpGaD
Metyrapone—CYP11B2—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	0.000141	0.00108	CbGpPWpGaD
Metyrapone—CYP11B2—Metabolism—TYMP—urinary bladder cancer	0.000141	0.00108	CbGpPWpGaD
Metyrapone—Headache—Methotrexate—urinary bladder cancer	0.000141	0.00238	CcSEcCtD
Metyrapone—Dizziness—Epirubicin—urinary bladder cancer	0.000139	0.00236	CcSEcCtD
Metyrapone—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—urinary bladder cancer	0.000137	0.00105	CbGpPWpGaD
Metyrapone—CYP11B2—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	0.000135	0.00104	CbGpPWpGaD
Metyrapone—Vomiting—Epirubicin—urinary bladder cancer	0.000134	0.00226	CcSEcCtD
Metyrapone—Nausea—Methotrexate—urinary bladder cancer	0.000133	0.00226	CcSEcCtD
Metyrapone—ABCC3—Metabolism—UGT2B7—urinary bladder cancer	0.000132	0.00101	CbGpPWpGaD
Metyrapone—Headache—Epirubicin—urinary bladder cancer	0.000132	0.00223	CcSEcCtD
Metyrapone—Dizziness—Doxorubicin—urinary bladder cancer	0.000129	0.00218	CcSEcCtD
Metyrapone—CYP11B2—Metabolism—NAT2—urinary bladder cancer	0.000127	0.000977	CbGpPWpGaD
Metyrapone—Nausea—Epirubicin—urinary bladder cancer	0.000125	0.00212	CcSEcCtD
Metyrapone—Vomiting—Doxorubicin—urinary bladder cancer	0.000124	0.0021	CcSEcCtD
Metyrapone—CYP2E1—Biological oxidations—GSTP1—urinary bladder cancer	0.000123	0.000944	CbGpPWpGaD
Metyrapone—ABCC3—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	0.000123	0.000941	CbGpPWpGaD
Metyrapone—Headache—Doxorubicin—urinary bladder cancer	0.000122	0.00206	CcSEcCtD
Metyrapone—CYP11B1—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	0.000122	0.000934	CbGpPWpGaD
Metyrapone—CYP11B1—Metabolism—TYMP—urinary bladder cancer	0.000121	0.000931	CbGpPWpGaD
Metyrapone—CYP2E1—Metapathway biotransformation—GSTP1—urinary bladder cancer	0.000121	0.000931	CbGpPWpGaD
Metyrapone—ABCC3—Metabolism—CYP4B1—urinary bladder cancer	0.000119	0.000912	CbGpPWpGaD
Metyrapone—CYP11B1—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	0.000116	0.000895	CbGpPWpGaD
Metyrapone—Nausea—Doxorubicin—urinary bladder cancer	0.000115	0.00196	CcSEcCtD
Metyrapone—CYP2E1—Biological oxidations—GSTM1—urinary bladder cancer	0.000113	0.000867	CbGpPWpGaD
Metyrapone—ABCC3—Metabolism—SLC19A1—urinary bladder cancer	0.000112	0.000861	CbGpPWpGaD
Metyrapone—CYP2E1—Metapathway biotransformation—GSTM1—urinary bladder cancer	0.000111	0.000855	CbGpPWpGaD
Metyrapone—CYP11B2—Metabolism—RRM2—urinary bladder cancer	0.00011	0.000844	CbGpPWpGaD
Metyrapone—CYP11B1—Metabolism—NAT2—urinary bladder cancer	0.00011	0.000842	CbGpPWpGaD
Metyrapone—ABCC3—Metabolism—PRSS3—urinary bladder cancer	0.000109	0.000839	CbGpPWpGaD
Metyrapone—CYP3A4—Biological oxidations—NAT2—urinary bladder cancer	0.000106	0.000815	CbGpPWpGaD
Metyrapone—CYP3A4—Metapathway biotransformation—NAT2—urinary bladder cancer	0.000105	0.000803	CbGpPWpGaD
Metyrapone—CYP11B2—Metabolism—HPGDS—urinary bladder cancer	0.000102	0.000781	CbGpPWpGaD
Metyrapone—CYP11B2—Metabolism—ENO2—urinary bladder cancer	0.000102	0.000781	CbGpPWpGaD
Metyrapone—CYP11B2—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	0.000101	0.000777	CbGpPWpGaD
Metyrapone—CYP11B2—Metabolism—GSTT1—urinary bladder cancer	9.87e-05	0.000758	CbGpPWpGaD
Metyrapone—CYP11B2—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	9.72e-05	0.000746	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—GSTZ1—urinary bladder cancer	9.53e-05	0.000731	CbGpPWpGaD
Metyrapone—CYP11B1—Metabolism—RRM2—urinary bladder cancer	9.47e-05	0.000727	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—GSTO2—urinary bladder cancer	9.03e-05	0.000693	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—NAT1—urinary bladder cancer	9.03e-05	0.000693	CbGpPWpGaD
Metyrapone—CYP11B1—Metabolism—ENO2—urinary bladder cancer	8.77e-05	0.000673	CbGpPWpGaD
Metyrapone—CYP11B1—Metabolism—HPGDS—urinary bladder cancer	8.77e-05	0.000673	CbGpPWpGaD
Metyrapone—ABCC3—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	8.76e-05	0.000673	CbGpPWpGaD
Metyrapone—ABCC3—Metabolism—TYMP—urinary bladder cancer	8.73e-05	0.000671	CbGpPWpGaD
Metyrapone—CYP11B1—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	8.72e-05	0.000669	CbGpPWpGaD
Metyrapone—CYP11B1—Metabolism—GSTT1—urinary bladder cancer	8.51e-05	0.000653	CbGpPWpGaD
Metyrapone—CYP3A4—Biological oxidations—HPGDS—urinary bladder cancer	8.48e-05	0.000651	CbGpPWpGaD
Metyrapone—ABCC3—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	8.39e-05	0.000644	CbGpPWpGaD
Metyrapone—CYP11B1—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	8.37e-05	0.000643	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—UGT2B7—urinary bladder cancer	8.26e-05	0.000634	CbGpPWpGaD
Metyrapone—CYP3A4—Biological oxidations—GSTT1—urinary bladder cancer	8.23e-05	0.000632	CbGpPWpGaD
Metyrapone—CYP11B2—Metabolism—NQO1—urinary bladder cancer	8.2e-05	0.00063	CbGpPWpGaD
Metyrapone—CYP11B2—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	7.96e-05	0.000611	CbGpPWpGaD
Metyrapone—ABCC3—Metabolism—NAT2—urinary bladder cancer	7.9e-05	0.000607	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—GSTZ1—urinary bladder cancer	7.53e-05	0.000578	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—CYP4B1—urinary bladder cancer	7.44e-05	0.000571	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—GSTO2—urinary bladder cancer	7.14e-05	0.000548	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—NAT1—urinary bladder cancer	7.14e-05	0.000548	CbGpPWpGaD
Metyrapone—CYP11B1—Metabolism—NQO1—urinary bladder cancer	7.07e-05	0.000543	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—SLC19A1—urinary bladder cancer	7.02e-05	0.000539	CbGpPWpGaD
Metyrapone—CYP11B2—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	6.94e-05	0.000533	CbGpPWpGaD
Metyrapone—CYP11B1—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	6.86e-05	0.000527	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—PRSS3—urinary bladder cancer	6.84e-05	0.000526	CbGpPWpGaD
Metyrapone—CYP11B2—Metabolism—GSTP1—urinary bladder cancer	6.84e-05	0.000525	CbGpPWpGaD
Metyrapone—ABCC3—Metabolism—RRM2—urinary bladder cancer	6.82e-05	0.000524	CbGpPWpGaD
Metyrapone—CYP11B2—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	6.62e-05	0.000508	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—UGT2B7—urinary bladder cancer	6.53e-05	0.000501	CbGpPWpGaD
Metyrapone—CYP11B2—Metabolism—TYMS—urinary bladder cancer	6.36e-05	0.000488	CbGpPWpGaD
Metyrapone—ABCC3—Metabolism—ENO2—urinary bladder cancer	6.31e-05	0.000485	CbGpPWpGaD
Metyrapone—ABCC3—Metabolism—HPGDS—urinary bladder cancer	6.31e-05	0.000485	CbGpPWpGaD
Metyrapone—CYP11B2—Metabolism—NCOR1—urinary bladder cancer	6.29e-05	0.000483	CbGpPWpGaD
Metyrapone—CYP11B2—Metabolism—GSTM1—urinary bladder cancer	6.29e-05	0.000483	CbGpPWpGaD
Metyrapone—ABCC3—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	6.28e-05	0.000482	CbGpPWpGaD
Metyrapone—ABCC3—Metabolism—GSTT1—urinary bladder cancer	6.12e-05	0.00047	CbGpPWpGaD
Metyrapone—ABCC3—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	6.03e-05	0.000463	CbGpPWpGaD
Metyrapone—CYP11B2—Metabolism—GPX1—urinary bladder cancer	6.02e-05	0.000462	CbGpPWpGaD
Metyrapone—CYP11B1—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	5.98e-05	0.000459	CbGpPWpGaD
Metyrapone—CYP11B2—Metabolism—ERCC2—urinary bladder cancer	5.91e-05	0.000454	CbGpPWpGaD
Metyrapone—CYP11B1—Metabolism—GSTP1—urinary bladder cancer	5.9e-05	0.000453	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—CYP4B1—urinary bladder cancer	5.88e-05	0.000451	CbGpPWpGaD
Metyrapone—ABCC3—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	5.73e-05	0.00044	CbGpPWpGaD
Metyrapone—CYP11B1—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	5.7e-05	0.000438	CbGpPWpGaD
Metyrapone—CYP3A4—Biological oxidations—GSTP1—urinary bladder cancer	5.7e-05	0.000438	CbGpPWpGaD
Metyrapone—CYP3A4—Metapathway biotransformation—GSTP1—urinary bladder cancer	5.62e-05	0.000432	CbGpPWpGaD
Metyrapone—CYP11B2—Metabolism—MTHFR—urinary bladder cancer	5.56e-05	0.000427	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—SLC19A1—urinary bladder cancer	5.55e-05	0.000426	CbGpPWpGaD
Metyrapone—CYP11B1—Metabolism—TYMS—urinary bladder cancer	5.48e-05	0.000421	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—TYMP—urinary bladder cancer	5.47e-05	0.00042	CbGpPWpGaD
Metyrapone—CYP11B1—Metabolism—NCOR1—urinary bladder cancer	5.42e-05	0.000416	CbGpPWpGaD
Metyrapone—CYP11B1—Metabolism—GSTM1—urinary bladder cancer	5.42e-05	0.000416	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—PRSS3—urinary bladder cancer	5.41e-05	0.000415	CbGpPWpGaD
Metyrapone—CYP3A4—Biological oxidations—GSTM1—urinary bladder cancer	5.24e-05	0.000402	CbGpPWpGaD
Metyrapone—CYP11B1—Metabolism—GPX1—urinary bladder cancer	5.19e-05	0.000398	CbGpPWpGaD
Metyrapone—CYP3A4—Metapathway biotransformation—GSTM1—urinary bladder cancer	5.17e-05	0.000397	CbGpPWpGaD
Metyrapone—CYP11B1—Metabolism—ERCC2—urinary bladder cancer	5.09e-05	0.000391	CbGpPWpGaD
Metyrapone—ABCC3—Metabolism—NQO1—urinary bladder cancer	5.09e-05	0.000391	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—NAT2—urinary bladder cancer	4.95e-05	0.00038	CbGpPWpGaD
Metyrapone—ABCC3—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	4.94e-05	0.000379	CbGpPWpGaD
Metyrapone—CYP11B1—Metabolism—MTHFR—urinary bladder cancer	4.79e-05	0.000368	CbGpPWpGaD
Metyrapone—CYP11B2—Metabolism—PPARG—urinary bladder cancer	4.51e-05	0.000346	CbGpPWpGaD
Metyrapone—CYP11B2—Metabolism—CREBBP—urinary bladder cancer	4.33e-05	0.000332	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—TYMP—urinary bladder cancer	4.32e-05	0.000332	CbGpPWpGaD
Metyrapone—ABCC3—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	4.31e-05	0.000331	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—RRM2—urinary bladder cancer	4.27e-05	0.000328	CbGpPWpGaD
Metyrapone—ABCC3—Metabolism—GSTP1—urinary bladder cancer	4.25e-05	0.000326	CbGpPWpGaD
Metyrapone—ABCC3—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	4.11e-05	0.000315	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—ENO2—urinary bladder cancer	3.96e-05	0.000304	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—HPGDS—urinary bladder cancer	3.96e-05	0.000304	CbGpPWpGaD
Metyrapone—ABCC3—Metabolism—TYMS—urinary bladder cancer	3.95e-05	0.000303	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—NAT2—urinary bladder cancer	3.91e-05	0.0003	CbGpPWpGaD
Metyrapone—ABCC3—Metabolism—GSTM1—urinary bladder cancer	3.9e-05	0.0003	CbGpPWpGaD
Metyrapone—ABCC3—Metabolism—NCOR1—urinary bladder cancer	3.9e-05	0.0003	CbGpPWpGaD
Metyrapone—CYP11B1—Metabolism—PPARG—urinary bladder cancer	3.88e-05	0.000298	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—GSTT1—urinary bladder cancer	3.84e-05	0.000295	CbGpPWpGaD
Metyrapone—ABCC3—Metabolism—GPX1—urinary bladder cancer	3.74e-05	0.000287	CbGpPWpGaD
Metyrapone—CYP11B1—Metabolism—CREBBP—urinary bladder cancer	3.73e-05	0.000286	CbGpPWpGaD
Metyrapone—ABCC3—Metabolism—ERCC2—urinary bladder cancer	3.67e-05	0.000282	CbGpPWpGaD
Metyrapone—CYP11B2—Metabolism—PTGS2—urinary bladder cancer	3.54e-05	0.000272	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—GSTZ1—urinary bladder cancer	3.49e-05	0.000268	CbGpPWpGaD
Metyrapone—ABCC3—Metabolism—MTHFR—urinary bladder cancer	3.45e-05	0.000265	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—RRM2—urinary bladder cancer	3.38e-05	0.000259	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—NAT1—urinary bladder cancer	3.31e-05	0.000254	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—GSTO2—urinary bladder cancer	3.31e-05	0.000254	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—NQO1—urinary bladder cancer	3.19e-05	0.000245	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—ENO2—urinary bladder cancer	3.13e-05	0.00024	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—HPGDS—urinary bladder cancer	3.13e-05	0.00024	CbGpPWpGaD
Metyrapone—CYP11B2—Metabolism—PTEN—urinary bladder cancer	3.09e-05	0.000237	CbGpPWpGaD
Metyrapone—CYP11B1—Metabolism—PTGS2—urinary bladder cancer	3.05e-05	0.000235	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—GSTT1—urinary bladder cancer	3.03e-05	0.000233	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—UGT2B7—urinary bladder cancer	3.03e-05	0.000233	CbGpPWpGaD
Metyrapone—CYP11B2—Metabolism—EP300—urinary bladder cancer	2.95e-05	0.000226	CbGpPWpGaD
Metyrapone—ABCC3—Metabolism—PPARG—urinary bladder cancer	2.8e-05	0.000215	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—CYP4B1—urinary bladder cancer	2.73e-05	0.000209	CbGpPWpGaD
Metyrapone—ABCC3—Metabolism—CREBBP—urinary bladder cancer	2.69e-05	0.000206	CbGpPWpGaD
Metyrapone—CYP11B1—Metabolism—PTEN—urinary bladder cancer	2.66e-05	0.000205	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—GSTP1—urinary bladder cancer	2.66e-05	0.000204	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—SLC19A1—urinary bladder cancer	2.57e-05	0.000198	CbGpPWpGaD
Metyrapone—CYP11B1—Metabolism—EP300—urinary bladder cancer	2.54e-05	0.000195	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—NQO1—urinary bladder cancer	2.52e-05	0.000193	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—PRSS3—urinary bladder cancer	2.51e-05	0.000193	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—TYMS—urinary bladder cancer	2.47e-05	0.00019	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—GSTM1—urinary bladder cancer	2.44e-05	0.000188	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—NCOR1—urinary bladder cancer	2.44e-05	0.000188	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—GPX1—urinary bladder cancer	2.34e-05	0.00018	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—ERCC2—urinary bladder cancer	2.3e-05	0.000176	CbGpPWpGaD
Metyrapone—ABCC3—Metabolism—PTGS2—urinary bladder cancer	2.2e-05	0.000169	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—MTHFR—urinary bladder cancer	2.16e-05	0.000166	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—GSTP1—urinary bladder cancer	2.1e-05	0.000161	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—TYMP—urinary bladder cancer	2.01e-05	0.000154	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—TYMS—urinary bladder cancer	1.95e-05	0.00015	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—NCOR1—urinary bladder cancer	1.93e-05	0.000148	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—GSTM1—urinary bladder cancer	1.93e-05	0.000148	CbGpPWpGaD
Metyrapone—ABCC3—Metabolism—PTEN—urinary bladder cancer	1.92e-05	0.000147	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—GPX1—urinary bladder cancer	1.85e-05	0.000142	CbGpPWpGaD
Metyrapone—ABCC3—Metabolism—EP300—urinary bladder cancer	1.83e-05	0.00014	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—ERCC2—urinary bladder cancer	1.82e-05	0.000139	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—NAT2—urinary bladder cancer	1.81e-05	0.000139	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—PPARG—urinary bladder cancer	1.75e-05	0.000134	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—MTHFR—urinary bladder cancer	1.71e-05	0.000131	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—CREBBP—urinary bladder cancer	1.68e-05	0.000129	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—RRM2—urinary bladder cancer	1.57e-05	0.00012	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—HPGDS—urinary bladder cancer	1.45e-05	0.000111	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—ENO2—urinary bladder cancer	1.45e-05	0.000111	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—GSTT1—urinary bladder cancer	1.41e-05	0.000108	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—PPARG—urinary bladder cancer	1.38e-05	0.000106	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—PTGS2—urinary bladder cancer	1.38e-05	0.000106	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—CREBBP—urinary bladder cancer	1.33e-05	0.000102	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—PTEN—urinary bladder cancer	1.2e-05	9.23e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—NQO1—urinary bladder cancer	1.17e-05	8.98e-05	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—EP300—urinary bladder cancer	1.15e-05	8.8e-05	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—PTGS2—urinary bladder cancer	1.09e-05	8.36e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	9.75e-06	7.49e-05	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—PTEN—urinary bladder cancer	9.49e-06	7.29e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—TYMS—urinary bladder cancer	9.06e-06	6.96e-05	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—EP300—urinary bladder cancer	9.05e-06	6.95e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	8.96e-06	6.88e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	8.96e-06	6.88e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—GPX1—urinary bladder cancer	8.58e-06	6.59e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	8.42e-06	6.47e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	7.92e-06	6.08e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—PPARG—urinary bladder cancer	6.42e-06	4.93e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	6.17e-06	4.74e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	5.05e-06	3.88e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—PTEN—urinary bladder cancer	4.41e-06	3.38e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—EP300—urinary bladder cancer	4.2e-06	3.23e-05	CbGpPWpGaD
